This week's **Parkinson's cognitive decline: Is Juvmo the answer we overlooked?** analysis reveals a persistent tension: we have new tools, but often miss basic risks. Clinicians are finally getting targeted therapies for long-standing problems, yet the diagnostic and preventative gaps remain stark.
1. **Juvmo's PD-MCI impact**: The FDA approval of Juvmo for Parkinson's disease with mild cognitive impairment offers a direct intervention for a critical, often overlooked, aspect of the disease. This is a step towards addressing cognitive decline, not just motor symptoms.
2. **Bariatric surgery's hidden hernia risk**: Up to 20% of bariatric surgery candidates present with pre-existing ventral hernias, a significant comorbidity often missed in pre-surgical evaluation. It matters. This oversight has direct implications for surgical planning and patient outcomes.
3. **IBD's silent years**: Inflammatory bowel disease may begin years before patients report symptoms, with subclinical inflammation detectable long before diagnosis. Clinicians noticed. This suggests a missed window for earlier intervention and disease modification.
The thread here is clear: better treatments arrive, but the fundamentals of patient assessment and early detection still lag. We are treating later, not always smarter. The pattern suggests a need to re-evaluate our intake protocols alongside our prescribing habits.
Clinicians should scrutinise pre-existing conditions and subclinical markers with the same intensity they apply to new drug regimens.
I read every reply.
